Form D · Pharmaceuticals
Intercure Ltd.
Hertzliya, L3 · CIK 0001857030
Offering snapshot reported Aug 19, 2026 · SEC filing
- Reported sold
- $0 Indefinite offering
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 15, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 19, 2026 | Initial | $0 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-594779
The transaction consisted of the first closing of an acquisition of ISHI (Botanico Ltd.) by Intercure Ltd. in consideration of InterCure's Ltd.'s ordinary shares and options to purchase ordinary shares.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Aug 19, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Amos Cohen | Executive |
| Gideon Hirschfeld | Director |
| Lennie Michelson Grinbaum | Director |
| Alexander Rabinovich | Director, Executive |
| David Salton | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
85 Medinat Ha Yehudim St.
Hertzliya, L3, 4676670
Hertzliya, L3, 4676670